[
    "uman epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 2012; 30: 1594-600 </p>Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of Women With Metastatic Breast Cancer by HER-2 Status and Trastuzumab Treatment: An Institutional-Based Review. J Clin Oncol 2010; 28:92-98 </p> Decker T, Fischer G, Bueke W, Bucke P, Stotz F, Gruneberger A, Gropp-Meier M, Wiedemann G, Pfeiffer C, Peschel C et al Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neupositive early breast cancer. J Cancer Res Clin Oncol 2012; 138: 1945-1950 \n\n Disis, ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER- 2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997;15:3363-3367 </p> Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K. Generation of T Ceil Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide-Based Vaccines. J Clin Onco 2002, 20:2024-2032</p>Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Can.2004. 4: 1 1-22 </p>Eiermann W; International Herceptin Study Group. Trastuzumab combined with chemotherapy for the treatment of HER-2-positive metastatic breast cancer: pivotal trial data. Ann Oncol. 2001; 12 Suppl 1 :857-62 </p> Fiore PD. 1987. ErbB-2 is a potent oncogene when overexpressed in N1\u0389/3T3 cells. Science 1987; 237: 178-182 </p> Franklin MC, Carey KD, Vajdos FF, et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004, 5:317-328 </p> Garpon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6:723-39 </p> Garg A, Li J, Clark E, Knott A, Carrothers TJ, Marier JF, Cortes J, Brewster M, Visich J, Lum B. Exposure-response analysis of pertuzumab in HER-2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters. Cancer Chemother Pharmacol 2013; 72: 1133-1 141 </p> Gelao L, Criscitielio C, Esposito A, Goldhirsch A, Curigliano G. Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an \u201cInnocent Bystander\u201d. Toxins 2014; 6:914-933 </p> Generali D, Bates G, Beiruti A, Brizzi VIP, Campo L, Bonardi S, Bersiga A, A!levi G, Milan! M, Aguggini S, Dogliotti L, Banham AH, Harris AL, Bottini A, Fox SB. Immunomodulation of FQXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res 2009; 15: 1046-1051 \n\n Geysen HM, Rodda SJ, Mason TJ. A priori delineation of a peptide which mimics a discontinuous antigenic determinant, Molecular immunology 1986; 23:709-15 </p> Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target Ann Oncol 2008; 19: 1523-1529 </p> Hafner C, Wagner S, Jasinska J, Allwardt D, Scheiner O, Wolff K, Pehamberger H, Wi"
]